MAIA reports 88% disease control rate in THIO-101 Phase 2 trial
MAIA Biotechnology reported strong efficacy data from its Phase 2 THIO-101 trial in non-small cell lung cancer, which provides a basis for future regulatory filings. The promising results indicate potential for accelerated approval and bolster the company's position in the immunotherapy market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed